Literature DB >> 8169791

Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.

L F Lacey1, O N Keene, C Duquesnoy, A Bye.   

Abstract

As indirect measures of rate of drug absorption (metrics), maximum plasma concentration (Cmax) is confounded by extent of drug absorption and the time to reach Cmax (tmax) is a discrete variable, dependent on blood sampling frequency. Building on the work of Endrenyi et al., we have compared different metrics, including Cmax/area under the curve of concentration versus time from time zero to infinity (AUC infinity), partial AUC from zero to tmax (AUCp), and Cmax.tmax with simulated experiments. Importantly, the performance of these metrics was assessed with the results of actual pharmacokinetic studies involving Glaxo drugs. The results of the simulated and real experiments were consistent and produced the following unambiguous findings: (1) Cmax/AUC infinity is a more powerful metric than Cmax in establishing bioequivalence when the formulations are truly bioequivalent; (2) Cmax/AUC infinity is more sensitive than Cmax at detecting differences in rate of absorption when they exist; and (3) the treatment ratios for AUCp, AUCp/AUC infinity, and Cmax.tmax are very imprecisely estimated and are of no practical value as measures of rate of absorption. Of the metrics examined, Cmax/AUC infinity is the most sensitive and powerful indirect measure of rate of drug absorption in comparative pharmacokinetic studies involving immediate-release dosage forms and should be used instead of Cmax in bioequivalence testing.

Mesh:

Year:  1994        PMID: 8169791     DOI: 10.1002/jps.2600830219

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  19 in total

1.  Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.

Authors:  R L Williams; W Adams; M L Chen; D Hare; A Hussain; L Lesko; R Patnaik; V Shah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Measures of exposure versus measures of rate and extent of absorption.

Authors:  M L Chen; L Lesko; R L Williams
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Estimation of Cmax and Tmax in populations after single and multiple drug administrations.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

5.  An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine.

Authors:  Dimitrios Psachoulias; Maria Vertzoni; James Butler; David Busby; Moira Symillides; Jennifer Dressman; Christos Reppas
Journal:  Pharm Res       Date:  2012-08-14       Impact factor: 4.200

Review 6.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Bioavailability of the iron formulated as natural ferric protein (TM/FMOA) and natural ferric protein + folic acid (TM/FMOA+FOL).

Authors:  E González-Peñas; P Martinez; M Gimeno; P Coronel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

8.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

9.  A comparison of six deconvolution techniques.

Authors:  F N Madden; K R Godfrey; M J Chappell; R Hovorka; R A Bates
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

10.  Metrics comparing simulated early concentration profiles for the determination of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; M L Chen
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.